Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke

BACKGROUND Analyses of some randomised trials show that calcium-channel blockers reduce the risk of stroke more than expected on the basis of mean blood pressure alone and that beta blockers are less effective than expected. We aimed to investigate whether the effects of these drugs on variability in blood pressure might explain these disparities in effect on stroke risk. METHODS The Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA) compared amlodipine-based regimens with atenolol-based regimens in 19 257 patients with hypertension and other vascular risk factors and the Medical Research Council (MRC) trial compared atenolol-based and diuretic-based regimens versus placebo in 4396 hypertensive patients aged 65-74 years. We expressed visit-to-visit variability of blood pressure during follow-up in the two trials as standard deviation (SD) and as transformations uncorrelated with mean blood pressure. For ASCOT-BPLA, we also studied within-visit variability and variability on 24 h ambulatory blood-pressure monitoring (ABPM). RESULTS In ASCOT-BPLA, group systolic blood pressure (SBP) SD was lower in the amlodipine group than in the atenolol group at all follow-up visits (p<0.0001), mainly because of lower within-individual visit-to-visit variability. Within-visit and ABPM variability in SBP were also lower in the amlodipine group than in the atenolol group (all p<0.0001). Analysis of changes from baseline showed that variability decreased over time in the amlodipine group and increased in the atenolol group. The lower risk of stroke in the amlodipine group (hazard ratio 0.78, 95% CI 0.67-0.90) was partly attenuated by adjusting for mean SBP during follow-up (0.84, 0.72-0.98), but was abolished by also adjusting for within-individual SD of clinic SBP (0.99, 0.85-1.16). Findings were similar for coronary events. In the ABPM substudy, reduced variability in daytime SBP in the amlodipine group (p<0.0001) partly accounted for the reduced risk of vascular events, but reduced visit-to-visit variability in clinic SBP had a greater effect. In the MRC trial, group SD SBP and all measures of within-individual visit-to-visit variability in SBP were increased in the atenolol group compared with both the placebo group and the diuretic group during initial follow-up (all p<0.0001). Subsequent temporal trends in variability in blood pressure during follow-up in the atenolol group correlated with trends in stroke risk. INTERPRETATION The opposite effects of calcium-channel blockers and beta blockers on variability of blood pressure account for the disparity in observed effects on risk of stroke and expected effects based on mean blood pressure. To prevent stroke most effectively, blood-pressure-lowering drugs should reduce mean blood pressure without increasing variability; ideally they should reduce both.

[1]  W. Elliott.  Prevention of Cardiovascular Events With an Antihypertensive Regimen of Amlodipine Adding Perindopril as Required Versus Atenolol Adding Bendroflumethiazide as Required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A Multicentre Randomised Controlled Tri , 2006 .

[2]  D. Su,et al.  Blood pressure variability is more important than blood pressure level in determination of end-organ damage in rats , 2006, Journal of Hypertension.

[3]  F. Mee,et al.  Accuracy of the SpaceLabs 90207 determined by the British Hypertension Society protocol. , 1991, Journal of hypertension.

[4]  Bryan Williams,et al.  Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate. , 2009, Journal of the American College of Cardiology.

[5]  P. Adab,et al.  Age-specific relevance of usual blood pressure to vascular mortality , 2003, The Lancet.

[6]  P. Rothwell,et al.  Regression dilution of systolic and diastolic blood pressure in patients with established cerebrovascular disease. , 2003, Journal of clinical epidemiology.

[7]  Yutaka Imai,et al.  Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. , 2005, Journal of hypertension.

[8]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[9]  N J Wald,et al.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009, BMJ : British Medical Journal.

[10]  N. Poulter,et al.  Blood Pressure Reduction Is Not the Only Determinant of Outcome , 2006, Circulation.

[11]  P. Rothwell,et al.  Reproducibility of Measures of Visit-to-Visit Variability in Blood Pressure after Transient Ischaemic Attack or Minor Stroke , 2009, Cerebrovascular Diseases.

[12]  F. Mee,et al.  19 An accurate automated device for home blood pressure measurement at last! The Omron HEM-705CP , 1994 .

[13]  B. Williams,et al.  Central aortic pressure and clinical outcomes. , 2009, Journal of hypertension.

[14]  W. Elliott.  Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients , 2009 .

[15]  F. Leenen.  Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome. , 2004, The Canadian journal of cardiology.

[16]  Piotr Ponikowski,et al.  2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, European heart journal.

[17]  P. Rothwell,et al.  Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension , 2010, The Lancet.

[18]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.

[19]  E. O’Brien,et al.  Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension , 2010, The Lancet.

[20]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[21]  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. , 1985, British medical journal.

[22]  Yutaka Imai,et al.  European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring , 2008, Journal of hypertension.

[23]  R. Collins,et al.  Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial— Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial , 2012, Drugs.

[24]  J. Staessen,et al.  Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. , 2004, American journal of hypertension.

[25]  M. Caulfield,et al.  Ambulatory blood pressure monitoring and 24-h blood pressure control as predictors of outcome in treated hypertensive patients , 2001, Journal of Human Hypertension.

[26]  Hans Wedel,et al.  Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). , 2009, Journal of the American College of Cardiology.

[27]  A. Rodgers,et al.  Global burden of blood-pressure-related disease, 2001 , 2008, The Lancet.

[28]  B Neal,et al.  Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials , 2008, BMJ : British Medical Journal.

[29]  A. Algra,et al.  Medium-Term Variability of Blood Pressure and Potential Underdiagnosis of Hypertension in Patients With Previous Transient Ischemic Attack or Minor Stroke , 2006, Stroke.

[30]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials. , 2004, Hypertension.

[31]  W. Elliott.  Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension , 2011 .

[32]  D. Su.  Treatment of hypertension based on measurement of blood pressure variability: lessons from animal studies , 2006, Current opinion in cardiology.

[33]  G. Bakris,et al.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. , 2008, The New England journal of medicine.

[34]  M. Caulfield,et al.  Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) , 2005, The Lancet.

[35]  B. Neal.  The Blood Pressure Lowering Treatment Trialists' Collaboration , 2001 .

[36]  J. Slattery,et al.  Blood pressure and risk of stroke in patients with cerebrovascular disease , 1996, BMJ.

[37]  D. Su,et al.  Arterial Baroreflex Deficit Induced Organ Damage in Sinoaortic Denervated Rats , 2001, Journal of cardiovascular pharmacology.

[38]  R. Collins,et al.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.

[39]  P. Rothwell,et al.  Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis , 2010, The Lancet.

[40]  Z. Li,et al.  Blood pressure, cholesterol, and stroke in eastern Asia , 1998, The Lancet.

[41]  M. Caulfield,et al.  Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients – an Anglo-Scandinavian cardiac outcomes trial substudy , 2009, Journal of hypertension.

[42]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[43]  J. Staessen,et al.  Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention , 2005, Hypertension.